<figure><img src="image_14.png" /></figure>

[643] Hill RS, Boyd AE. Perifusion of a clonal cell line of Simian virus 40-transformed beta cells. Insulin secretory dynamics in response to glucose, 3-isobutyl-1-methylxanthine, and potassium. 3rd Diabetes 1985;34:115-20.

[644] Harndahl L, Jing XJ, Ivarsson R, Degerman E, Ahren B, Manganiello VC, et al. Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem 2002;277: 37446-55.

[645] Harndahl L, Wierup N, Enerback S, Mulder H, Manganiello VC, Sundler F, et al. Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem 2004;279:15214-22.

[646] Dostmann WR, Taylor SS. Identifying the molecular switches that determine whether (Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-dependent protein kinase I. Biochemistry 1991;30:8710-6.

[647] Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990;59:971-1005.

[648] Ashby CD, Walsh DA. Characterization of the interaction of a protein inhibitor with adenosine 3',5'-monophosphate-dependent protein kinases. I. Interaction with the catalytic subunit of the protein kinase. J Biol Chem 1972;247: 6637-42.

[649] Beavo JA, Bechtel PJ, Krebs EG. Activation of protein kinase by physiological concentrations of cyclic AMP. Proc Natl Acad Sci U S A 1974;71:3580-3.

[650] Beguin P, Nagashima K, Nishimura M, Gonoi T, Seino S. PKA-mediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J 1999;18:4722-32.

[651] Ribalet B, Ciani S, Eddlestone GT. ATP mediates both activation and inhibition of K(ATP) channel activity via cAMP-dependent protein kinase in insulin-secreting cell lines. J Gen Physiol 1989;94:693-717.

[652] Bunemann M, Gerhardstein BL, Gao T, Hosey MM. Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit. J Biol Chem 1999;274:33851-4.

[653] De Jongh KS, Murphy BJ, Colvin AA, Hell JW, Takahashi M, Catterall WA. Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3',5'-cyclic monophosphate-dependent protein kinase. Biochemistry 1996;35:10392-402.

[654] Gao T, Puri TS, Gerhardstein BL, Chien AJ, Green RD, Hosey MM. Identification and subcellular localization of the subunits of L-type calcium channels and adenyllyl cyclase in cardiac myocytes. J Biol Chem 1997;272:19401-7.

[655] Leiser M, Fleischer N. cAMP-dependent phosphorylation of the cardiac-type alpha 1 subunit of the voltage-dependent Ca2+ channel in a murine pancreatic beta-cell line. Diabetes 1996;45:1412-8.

[656] Safayhi H, Haase H, Kramer U, Bihlmayer A, Roenfeldt M, Ammon HP, et al. L-type calcium channels in insulin-secreting cells: biochemical characterization and phosphorylation in RINm5F cells. Mol Endocrinol 1997;11:619-29.

[657] Ammala C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature 1993;363:356-8.

[658] Kanno T, Suga S, Wu J, Kimura M, Wakui M. Intracellular cAMP potentiates voltage-dependent activation of L-type Ca2+ channels in rat islet beta-cells. Pflügers Archiv 1998;435:578-80.

[659] MacDonald PE, Wang X, Xia F, El-kholy W, Targonsky ED, Tsushima RG, et al. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 2003;278:52446-53.

[660] Wang X, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 2001;142:1820-7.

[661] Miura Y, Matsui H. Glucagon-like peptide-1 induces a cAMP-dependent increase of [Na+]i associated with insulin secretion in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2003;285:E1001-9.

[662] Hisatomi M, Hidaka H, Niki I. Ca2+/calmodulin and cyclic 3,5' adenosine monophosphate control movement of secretory granules through protein phosphorylation/dephosphorylation in the pancreatic beta-cell. Endocrinology 1996;137:4644-9.

[663] Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004;95:252-62.

[664] Renstrom E, Eliasson L, Rorsman P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997;502(Pt 1):105-18.

[665] Montague W, Howell SL. The mode of action of adenosine 3',5'-cyclic monophosphate in mammalian islets of Langerhans. Preparation and properties of islet-cell protein phosphokinase. Biochem J 1972;129:551-60.

[666] Chepurny OG, Kelley GG, Dzhura I, Leech CA, Roe MW, Dzhura E, et al. PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM in human islets of Langerhans. Am J Physiol Endocrinol Metab 2010;298:E622-33.

[667] Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004;53:5-13.

[668] Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol 2006;577:5-15.

[669] Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, et al. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 2001;276:46046-53.

[670] Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-93.

[671] Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 1999;274: 14147-56.

[672] Kang G, Chepurny OG, Holz GG. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 2001;536:375-85.

[673] Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, Rutter GA. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J 2003;369: 287-99.

[674] Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 1989;38:338-42.

[675] Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Therapeut 2008;46:273-9.

[676] Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;81:161-8.

[677] Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.

[678] Ponzani P, Scardapane M, Nicolucci A, Rossi MC. Effectiveness and safety of liraglutide after three years of treatment. Minerva Endocrinol 2016;41:35-42.
[679] Tanaka K, Saisho Y, Kawai T, Tanaka M, Meguro S, Irie J, et al. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr J 2015;62:399-409.

[680] Vilsboll T, Krarup T, Madsbad S, Holst JJ. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intra-venous glucose. Diabet Med 2001;18:144-9.

[681] Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46.

[682] de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007;56:438-43.

[683] Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997;46:615-21.

[684] Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 2002;277:50497-502.

[685] Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000;2:805-11.

[686] Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S. Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis. J Biol Chem 2004;279:7956-61.

[687] Shigeto M, Ramracheya R, Tarasov AI, Cha CY, Chibalina MV, Hastoy B, et al. GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. J Clin Investig 2015;125:4714-28.

[688] Takahashi N, Kishimoto T, Nemoto T, Kadowaki T, Kasai H. Fusion pore dynamics and insulin granule exocytosis in the pancreatic islet. Science 2002;297:1349-52.

[689] Eliasson L, Ma X, Renstrom E, Barg S, Berggren PO, Galvanovskis J, et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 2003;121:181-97.

[690] Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:159-66.

[691] Hay CW, Sinclair EM, Bermano G, Durward E, Tadayyon M, Docherty K. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. J Endocrinol 2005;186:353-65.

[692] Fehmann HC, Habener JF. Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-1(7-37) in mouse insulinoma beta TC-1 cells. Endocrinology 1992;130:2890-6.

[693] Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5.

[694] Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995;136:4910-7.

[695] Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 2005;48:2140-6.

[696] Pacini G, Thomaseth K, Ahren B. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Metabolism 2010;59:988-92.

[697] Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 2004;53:2359-65.

[698] Tura A, Bizzotto R, Yamada Y, Seino Y, Pacini G, Ahren B. Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. Am J Physiol Regul Integr Comp Physiol 2018;314:R639-46.

[699] Tura A, Pacini G, Yamada Y, Seino Y, Ahren B. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. Am J Physiol Regul Integr Comp Physiol 2019;316:R27-37.

[700] Duckworth WC, Hamel FG, Peavy DE. Hepatic metabolism of insulin. Am J Med 1988;85:71-6.

[701] Goodison S, Kenna S, Ashcroft SJ. Control of insulin gene expression by glucose. Biochem J 1992;285(Pt 2):563-8.

[702] Wang X, Cahill CM, Pineyro MA, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 1999;140:4904-7.

[703] Campbell JE, Ussher JR, Mulvihill EE, Kolic J, Baggio LL, Cao X, et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med 2016;22:84-90.

[704] Dupre J, Curtis JD, Unger RH, Waddell RW, Beck JC. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Investig 1969;48:745-57.

[705] Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978;103:610-5.

[706] Jensen SL, Holst JJ, Nielsen OV, Lauritsen KB. Secretory effects of gastric inhibitory polypeptide on the isolated perfused porcine pancreas. Acta Physiol Scand 1981;111:233-8.

[707] Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009;137:2146-57.

[708] Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:14843-7.

[709] Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 1998;47:1046-52.

[710] Sparre-Ulrich AH, Gabe MN, Gasbjerg LS, Christiansen CB, Svendsen B, Hartmann B, et al. GIP(3-30)NH(2) is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem Pharmacol 2017;131:78-88.

[711] El K, Gray SM, Capozzi ME, Knuth ER, Jin E, Svendsen B, et al. GIP mediates the incretin effect and glucose tolerance by dual actions on alpha cells and beta cells. Sci Adv 2021;7.

[712] de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008;51:2263-70.

[713] Opara EC, Go VL. Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells. Regul Pept 1991;32:65-73.

[714] Bailey CJ, Wilkes LC, Conlon JM, Armstrong PH, Buchanan KD. Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinol 1990;125:375-9.
[715] Ahren B, Lundquist I. Influences of gastro-intestinal polypeptides and glucose on glucagon secretion induced by cholinergic stimulation. Horm Metab Res 1982;14:529-32.

[716] Malmgren S, Ahren B. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 2015;58:1091-9.

[717] McShane LM, Irwin N, O'Flynn D, Franklin ZJ, Hewage CM, O'Harte FP. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice. J Endocrinol 2016;229:319-30.

[718] Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biol Chem 2008;389:189-93.

[719] Szecowka J, Lins PE, Efendic S. Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats. Endocrinology 1982;110:1268-72.

[720] Schusdziarra V, Rouiller D, Unger RH. Gastric glucagon release during gastric and intestinal phase of a meal in dogs. Am J Physiol 1980;238: G109-13.

[721] Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46: 798-801.

[722] Christensen MB, Calanna S, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 2014;99:E418-26.

[723] Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011;300: E1038-46.

[724] Christensen MB. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Dan Med J 2016;63.

[725] Dupre J, Caussignac Y, McDonald TJ, Van Vliet S. Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. J Clin Endocrinol Metab 1991;72:125-9.

[726] Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metabol 2015;17:414-22.

[727] Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. Diabetes Care 2016;39:1241-9.

[728] Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342-9.

[729] Capozzi ME, Wait JB, Koech J, Gordon AN, Coch RW, Svendsen B, et al. Glucagon lowers glycemia when beta-cells are active. JCI Insight 2019;5.

[730] Zhu L, Dattaroy D, Pham J, Wang L, Barella LF, Cui Y, et al. Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. JCI Insight 2019;5.

[731] Richter MM, Galsgaard KD, Elmelund E, Knop FK, Suppli MP, Holst JJ, et al. The liver-alpha-cell Axis in health and in disease. Diabetes 2022;71:1852-61.

[732] Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996;45:257-61.

[733] Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2

(noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81: 327-32.

[734] Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Gluca- gonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-6.

[735] Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucago- nostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010;59:1765-70.

[736] Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994;43:104-8.

[737] Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsboll T. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. J Hepatol 2016;64:908-15.

[738] Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Vilsboll T, Knop FK, et al. The role of efferent cholinergic transmission for the insulinotropic and glu- cagonostatic effects of GLP-1. Am J Physiol Regul Integr Comp Physiol 2015;309:R544-51.

[739] Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22.

[740] Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997;46:792-800.

[741] Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, et al. A single-cell transcriptome atlas of the human pancreas. Cell Syst 2016;3: 385-394 e383.

[742] Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab 2016;24:593-607.

[743] Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 2015;28:391-402.

[744] Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014;63:1224-33.

[745] Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. The new biology and pharmacology of glucagon. Physiol Rev 2017;97:721-66.

[746] Schmid R, Schusdziarra V, Aulehner R, Weigert N, Classen M. Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. Z Gastroenterol 1990;28:280-4.

[747] Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46: 3-19.

[748] Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005;307:380-4.

[749] Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl 3):S16-21.

[750] Sarnobat D, Moffett RC, Gault VA, Tanday N, Reimann F, Gribble FM, et al. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu(CreER-T2);ROSA26-eYFP mice. Peptides 2020;125:170205.

[751] Marenah L, McCluskey JT, Abdel-Wahab YH, O'Harte FP, McClenaghan NH, Flatt PR. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol Chem 2006;387:941-7.
[752] Arden KC. Biggs 3rd WH. Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling. Arch Biochem Biophys 2002;403:292-8.

[753] Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.

[754] Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002;22:2025-36.

[755] Tran H, Brunet A, Grenier JM, Datta SR, Fornace Jr AJ, DiStefano PS, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002;296:530-4.

[756] Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005;280: 22297-307.

[757] Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002;174:233-46.

[758] Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-70.

[759] Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009;284: 30372-82.

[760] Widenmaier SB, Sampaio AV, Underhill TM, McIntosh CH. Noncanonical activation of Akt/protein kinase B in beta-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem 2009;284: 10764-73.

[761] Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006;4:391-406.

[762] Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741-50.

[763] Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003;144:4433-45.

[764] Tschen SI, Dhawan S, Gurlo T, Bhushan A. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 2009;58:1312-20.

[765] Köhler CU, Olewinski M, Tannapfel A, Schmidt WE, Fritsch H, Meier JJ. Cell cycle control of beta-cell replication in the prenatal and postnatal human pancreas. Am J Physiol 2011;300:E 221-230.

[766] Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Bottcher A, Sanchez-Garrido MA, et al. Targeted pharmacological therapy restores beta-cell function for diabetes remission. Nat Metab 2020;2:192-209.

[767] Ackeifi C, Wang P, Karakose E, Manning Fox JE, Gonzalez BJ, Liu H, et al. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human beta cell regeneration. Sci Transl Med 2020;12.

[768] Rosselot C, Li Y, Wang P, Alvarsson A, Beliard K, Lu G, et al. Harmine and exendin-4 combination therapy safely expands human beta cell mass in vivo in a mouse xenograft system. Sci Transl Med 2024;16:eadg3456.

[769] Ebert R, Creutzfeldt W. Metabolic effects of gastric inhibitory polypeptide. Front Horm Res 1987;16:175-85.

[770] Dupre J, Greenidge N, McDonald T.J., Ross SA, Rubinstein D. Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 1976;25:1197-9.

[771] Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue. J Nutr 1995;125:183-8.

[772] Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992;287(Pt 2):337-47.

[773] Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996;37:693-707.

[774] Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002;43:1997-2006.

[775] Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002;13:471-81.

[776] Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Investig 1981;68:1106-7.

[777] Jorde R, Pettersen JE, Burhol PG. Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of Intralipid in man. Acta Med Scand 1984;216:19-23.

[778] Ohneda A, Kobayashi T, Nihei J. Effect of endogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs. Regul Pept 1983;6:25-32.

[779] Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bulow J. Glucose-dependent insulinotropic polypeptide may enhance fatty acid reesterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010;59:2160-3.

[780] Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267-72.

[781] Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Sparre-Ulrich AH, Rosenkilde MM, et al. The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes 2017;66:2363-71.

[782] Asmar M, Arngrim N, Simonsen L, Asmar A, Nordby P, Holst JJ, et al. The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss. Nutr Diabetes 2016;6:e208.

[783] Varol C, Zvibel I, Spektor L, Mantelmacher FD, Vugman M, Thurm T, et al. Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation. J Immunol 2014;193:4002-9.

[784] Mantelmacher FD, Zvibel I, Cohen K, Epshtein A, Pasmanik-Chor M, Vogl T, et al. GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9. Nat Metab 2019;1:58-69.

[785] Hammoud R, Kaur KD, Koehler JA, Baggio LL, Wong CK, Advani KE, et al. Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice. JCI Insight 2024 Dec 26;10(3):e174825. https://doi.org/10.1172/jci.insight.174825.

[786] Allen DO, Quesenberry JT. Quantitative differences in the cyclic AMP-lipolysis relationships for isoproterenol and forskolin. J Pharmacol Exp Therapeut 1988;244:852-8.

[787] Sengupta K, Long KJ, Allen DO. Relationship among isoproterenol, cyclic AMP, cyclic AMP-dependent protein kinase and lipolysis in perfused fat cells. J Pharmacol Exp Therapeut 1981;218:128-33.

[788] Sengupta K, Long KJ, Allen DO. Growth hormone stimulation of lipolysis and cyclic AMP levels in perfused fat cells. J Pharmacol Exp Therapeut 1981;217:15-9.
[789] Yeaman SJ. Hormone-sensitive lipase—a multipurpose enzyme in lipid metabolism. Biochim Biophys Acta 1990;1052:128–32.

[790] Butcher RW, Sneyd JG, Park CR, Sutherland Jr EW. Effect of insulin on adenosine 3',5'-monophosphate in the rat epididymal fat pad. J Biol Chem 1966;241:1651–3.

[791] Elks ML, Manganiello VC, Vaughan M. Hormone-sensitive particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes. Regulation of responsiveness by dexamethasone. J Biol Chem 1983;258:8582–7.

[792] Londos C, Honnor RC, Dhillon GS. cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J Biol Chem 1985;260:15139–45.

[793] Wong EH, Loten EG. The antilipolytic action of insulin on adrenocorticotrophin-stimulated rat adipocytes. The roles of adenosine 3',5'-monophosphate and the protein kinase dependent on adenosine 3',5'-monophosphate. Eur J Biochem 1981;115:17–22.

[794] Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, et al. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab 2013;304:E1–13.

[795] Zhang Q, Delessa CT, Augustin R, Bakhti M, Colden G, Drucker DJ, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab 2021;33:833–844 e835.

[796] Heimburger SMN, Nielsen CN, Calanna S, Holst JJ, Vilsboll T, Knop FK, et al. Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: a randomized, double-blind, placebo-controlled, crossover clinical trial. Diabetes Obes Metabol 2022;24:142–7.

[797] Szalowska E, Meijer K, Kloosterhuis N, Razaee F, Priebe M, Vonk RJ. Subchronic administration of stable GIP analog in mice decreases serum LPL activity and body weight. Peptides 2011;32:938–45.

[798] Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CH. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 2012;7:e40156.

[799] Yu X, Chen S, Funcke JB, Straub LG, Pirro V, Emont MP, et al. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell Metab 2025 Jan 7;37(1):187–204.e7. https://doi.org/10.1016/j.cmet.2024.11.003.

[800] Isken F, Pfeiffer AF, Nogueiras R, Osterhoff MA, Ristow M, Thorens B, et al. Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice. Am J Physiol Endocrinol Metab 2008;295:E350–5.

[801] Takahashi Y, Fujita H, Seino Y, Hattori S, Hidaka S, Miyakawa T, et al. Gastric inhibitory polypeptide receptor antagonism suppresses intramuscular adipose tissue accumulation and ameliorates sarcopenia. J Cachexia Sarcopenia Muscle 2023 Dec;14(6):2703–18. https://doi.org/10.1002/jcsm.13346.

[802] Yamada C, Yamada Y, Tsukiyama K, Yamada K, Yamane S, Harada N, et al. Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes. Biochem Biophys Res Commun 2007;364:175–80.

[803] Boer GA, Keenan SN, Miotto PM, Holst JJ, Watt MJ. GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. Am J Physiol Endocrinol Metab 2021;320:E835–45.

[804] Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738–42.

[805] Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Investig 2007;117:143–52.

[806] Svendsen B, Capozzi ME, Nui J, Hannou SA, Finan B, Naylor J, et al. Pharmacological antagonism of the incretin system protects against diet-induced obesity. Mol Metabol 2020;32:44–55.

[807] Joo E, Harada N, Yamane S, Fukushima T, Taura D, Iwasaki K, et al. Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice. Diabetes 2017;66:868–79.

[808] Beaudry JL, Kaur KD, Varin EM, Baggio LL, Cao X, Mulvihill EE, et al. Physiological roles of the GIP receptor in murine brown adipose tissue. Mol Metabol 2019;28:14–25.

[809] Heimburger SMN, Hoe B, Nielsen CN, Bergman NC, Skov-Jeppesen K, Hartmann B, et al. GIP affects hepatic fat and Brown adipose tissue thermogenesis but not white adipose tissue transcriptome in type 1 diabetes. J Clin Endocrinol Metab 2022;107:3261–74.

[810] Lloret MJ, Fusaro M, Jorgensen HS, Haarhaus M, Gifre L, Alfieri CM, et al. Evaluating osteoporosis in chronic kidney disease: both bone quantity and quality matter. J Clin Med 2024;13.

[811] Ott SM. Cortical or trabecular bone: what's the difference? Am J Nephrol 2018;47:373–5.

[812] Bouvard B, Mabilleau G. Gut hormones and bone homeostasis: potential therapeutic implications. Nat Rev Endocrinol 2024 Sep;20(9):553–64. https://doi.org/10.1038/s41574-024-01000-z.

[813] Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 2008;23:536–43.

[814] Hansen MS, Soe K, Christensen LL, Fernandez-Guerra P, Hansen NW, Wyatt RA, et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur J Endocrinol 2023;188.

[815] Mieczkowska A, Bouvard B, Chappard D, Mabilleau G. Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures. Bone 2015;74:29–36.

[816] Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol 2011;11:12.

[817] Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006;20:1644–51.

[818] Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007;292:E543–8.

[819] Gabe MBN, Skov-Jeppesen K, Gasbjerg LS, Schiellerup SP, Martinussen C, Gadgaard S, et al. GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacol Res 2022;176:106058.

[820] Torekov SS, Harslof T, Rejnmark L, Eiken P, Jensen JB, Herman AP, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014;99:E729–33.

[821] Styrkarsdottir U, Tragante V, Stefansdottir L, Thorleifsson G, Oddsson A, Sorensen E, et al. Obesity variants in the GIPR gene are not associated with risk of fracture or bone mineral density. J Clin Endocrinol Metab 2024;109: e1608–15.

[822] Yavropoulou MP, Yovos JG. Incretins and bone: evolving concepts in nutrient-dependent regulation of bone turnover. Hormones (Basel) 2013;12:214–23.

[823] Nissen A, Christensen M, Knop FK, Vilsboll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 2014;99:E2325–9.

[824] Ferrone M, Geraci M. A review of the relationship between parenteral nutrition and metabolic bone disease. Nutr Clin Pract 2007;22:329–39.

[825] Hamilton C, Seidner DL. Metabolic bone disease and parenteral nutrition. Curr Gastroenterol Rep 2004;6:335–41.
[826] Clowes JA, Robinson RT, Heller SR, Eastell R, Blumsohn A. Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab 2002;87:3324-9.

[827] Sherk VD, Schauer I, Shah VN. Update on the acute effects of glucose, insulin, and incretins on bone turnover in vivo. Curr Osteoporos Rep 2020;18: 371-7.

[828] Stensen S, Gasbjerg LS, Helsted MM, Hartmann B, Christensen MB, Knop FK. GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications. Peptides 2020;125:170197.

[829] Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 2003;88:4867-73.

[830] Hartmann B, Longo M, Mathiesen DS, Hare KJ, Jorgensen NR, Esposito K, et al. Signs of a glucose- and insulin-independent gut-bone Axis and aberrant bone homeostasis in type 1 diabetes. J Clin Endocrinol Metab 2023;109: e259-65.

[831] Mabilleau G, Perrot R, Mieczkowska A, Boni S, Flatt PR, Irwin N, et al. Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption. Bone 2016;91:102-12.

[832] Skov-Jeppesen K, Veedfald S, Madsbad S, Holst JJ, Rosenkilde MM, Hartmann B. Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study. Bone 2021;152:116065.

[833] Christensen MB, Lund A, Calanna S, Jorgensen NR, Holst JJ, Vilsboll T, et al. Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia. J Clin Endocrinol Metab 2018;103: 288-94.

[834] Lund A, Bagger J, Christensen M, Frost M, Jørgensen N, Storkholm JH, et al. Gut Hormones, rather than glucose or insulin, are the main drivers of diminished bone resorption in the postabsorptive state. Diabetes 2016. P-1895, https://www.easd.org/media-centre/home.html?urlTarget=_blank#! resources/gut-hormones-rather-than-glucose-or-insulin-are-the-main-drivers-of-diminished-bone-resorption-in-the-postabsorptive-state.

[835] Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007;40:1352-60.

[836] Gobron B, Bouvard B, Vyavahare S, Blom LV, Pedersen KK, Windelov JA, et al. Enteroendocrine K cells exert complementary effects to control bone quality and mass in mice. J Bone Miner Res 2020;35:1363-74.

[837] Gaudin-Audrain C, Irwin N, Mansur S, Flatt PR, Thorens B, Basle M, et al. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone 2013;53: 221-30.

[838] Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone 2013;56:337-42.

[839] Mantelmacher FD, Fishman S, Cohen K, Pasmanik Kor M, Yamada Y, Zivibel I, et al. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to impaired bone marrow hematopoiesis. J Immunol 2017;198:3089-98.

[840] Pujadas G, Varin EM, Baggio LL, Mulvihill EE, Bang KWA, Koehler JA, et al. The gut hormone receptor GIPR links energy availability to the control of hematopoiesis. Mol Metabol 2020;39:101008.

[841] Mabilleau G, Gobron B, Mieczkowska A, Perrot R, Chappard D. Efficacy of targeting bone-specific GIP receptor in ovariectomy-induced bone loss. J Endocrinol 2018;239:215-27.

[842] Daley EJ, Trackman PC. beta-Catenin mediates glucose-dependent insulinotropic polypeptide increases in lysyl oxidase expression in osteoblasts. BoneKEy Rep 2021;14:101063.

[843] Mabilleau G, Mieczkowska A, Irwin N, Simon Y, Audran M, Flatt PR, et al. Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties. Bone 2014;63:61-8.

[844] Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, et al. Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus. J Cell Physiol 2015;230:3009-18.

[845] Vyavahare SS, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilleau G. GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice. Peptides 2020;125:170207.

[846] Mieczkowska A, Bouvard B, Legrand E, Mabilleau G. [Gly(2)]-GLP-2, but not glucagon or [D-Ala(2)]-GLP-1, controls collagen crosslinking in murine osteoblast cultures. Front Endocrinol 2021;12:721506.

[847] Gobron B, Couchot M, Irwin N, Legrand E, Bouvard B, Mabilleau G. Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility. J Bone Miner Res 2023;38: 733-48.

[848] Hiromura M, Mori Y, Kohashi K, Terasaki M, Shinmura K, Negoro T, et al. Suppressive effects of glucose-dependent insulinotropic polypeptide on cardiac hypertrophy and fibrosis in angiotensin II-infused mouse models. Circ J 2016;80:1988-97.

[849] Ussher JR, Campbell JE, Mulvihill EE, Baggio LL, Bates HE, McLean BA, et al. Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction. Cell Metab 2018;27:450-460 e456.

[850] Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, et al. GLP-1 receptor expression within the human heart. Endocrinology 2018;159:1570-84.

[851] Quaife-Ryan GA, Sim CB, Ziemann M, Kaspi A, Rafehi H, Ramialison M, et al. Multicellular transcriptional analysis of mammalian heart regeneration. Circulation 2017;136:1123-39.

[852] Karstoft K, Mortensen SP, Knudsen SH, Solomon TP. Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics. Am J Physiol Endocrinol Metab 2015;308:E426-33.

[853] Skov-Jeppesen K, Svane MS, Martinussen C, Gabe MBN, Gasbjerg LS, Veedfald S, et al. GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men. Bone 2019;125:178-85.

[854] Wang S, Oestricker LZ, Wallendorf MJ, Sterl K, Dunai J, Kilpatrick CR, et al. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. PLoS One 2018;13:e0192441.

[855] Heimburger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides 2020;125:170174.

[856] Kizilkaya HS, Sorensen KV, Kibsgaard CJ, Gasbjerg LS, Hauser AS, Sparre-Ulrich AH, et al. Loss of function glucose-dependent insulinotropic polypeptide receptor variants are associated with alterations in BMI, bone strength and cardiovascular outcomes. Front Cell Dev Biol 2021;9:749607.

[857] Kureishi Bando Y, Remina YR, Kamihara TK, Nishimura E, Murohara TM. The aging-induced hyperexcretion of glucose-dependent insulinotropic peptide is essential for the healthy cardiac remodeling by prevention of cardiac ceramide accumulation. Eur Heart J 2020;41. ehaa946.3615.

[858] Hoizumi M, Sato T, Shimizu T, Kato S, Tsukiyama K, Narita T, et al. Inhibition of GIP signaling extends lifespan without caloric restriction. Biochem Biophys Res Commun 2019;513:974-82.

[859] Heather LC, Gopal K, Srnic N, Ussher JR. Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology. Diabetes 2024;73:659-70.

[860] Kumar S, Wang G, Liu W, Ding W, Dong M, Zheng N, et al. Hypoxia-induced mitogenic factor promotes cardiac hypertrophy via calcium-dependent and hypoxia-inducible factor-1alpha mechanisms. Hypertension 2018;72:331-42.

[861] Hiromura M, Mori Y, Terasaki M, Kushima H, Saito T, Osaka N, et al. Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis
in diabetic mice via suppression of TGF-beta2. Diabetes Vasc Dis Res 2021;18:1479164121999034.

[862] Kahles F, Ruckbeil MV, Arrivas MC, Mertens RW, Moellmann J, Biener M, et al. Association of glucose-dependent insulinotropic polypeptide levels with cardiovascular mortality in patients with acute myocardial infarction. J Am Heart Assoc 2021;10:e019477.

[863] Kahles F, Rau M, Reugels M, Foldenauer AC, Mertens RW, Arrivas MC, et al. The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury. Cardiovasc Diabetol 2022;21:18.

[864] Jujic A, Atabaki-Pasdar N, Nilsson PM, Almgren P, Hakaste L, Tuomi T, et al. Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia 2020;63:1043-54.

[865] Kahles F, Ruckbeil MV, Mertens RW, Foldenauer AC, Arrivas MC, Moellmann J, et al. Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. Eur Heart J 2020;41:882-9.

[866] Berglund LM, Lyssenko V, Ladenvall C, Kotova O, Edsfeldt A, Pilgaard K, et al. Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB. Diabetes 2016;65: 239-54.

[867] Nitz I, Fisher E, Weikert C, Burwinkel B, Li Y, Mohlig M, et al. Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol Nutr Food Res 2007;51:1046-52.

[868] Sugunan D, Nair AK, Kumar H, Gopalakrishnapillai A. A case-control analysis of common variants in GIP with type 2 diabetes and related biochemical parameters in a South Indian population. BMC Med Genet 2010;11:118.

[869] Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Therapeut 2010;332:274-80.

[870] Gabe MBN, van der Velden WJC, Gadgaard S, Smit FX, Hartmann B, Brauner-Osborne H, et al. Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system. Basic Clin Pharmacol Toxicol 2020;126(Suppl 6):122-32.

[871] Mohammad S, Patel RT, Bruno J, Panhwar MS, Wen J, McGraw TE. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity. Mol Cell Biol 2014;34:3618-29.

[872] Yammine L, Picatoste B, Abdullah N, Leahey RA, Johnson EF, Gomez-Banoy N, et al. Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant. Mol Metabol 2023;78:101831.

[873] Berndt SI, Gustafsson S, Magi R, Ganna A, Wheeler E, Feitosa MF, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 2013;45: 501-12.

[874] Graff M, Scott RA, Justice AE, Young KL, Feitosa MF, Barata L, et al. Genome-wide physical activity interactions in adiposity - a meta-analysis of 200,452 adults. PLoS Genet 2017;13:e1006528.

[875] Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluoglu AM, et al. Genetically predicted glucose-dependent insulinotropic polypeptide (GIP) levels and cardiovascular disease risk are driven by distinct causal variants in the GIPR region. Diabetes 2021;70:2706-19.

[876] Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, et al. Genetic variation in GIP influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42:142-8.

[877] Karhunen V, Daghlas I, Zuber V, Vujkovic M, Olsen AK, Knudsen LB, et al. Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. Diabetologia 2021;64:2773-8.

[878] Koffert J, Honka H, Teuho J, Kauhanen S, Hurme S, Parkkola R, et al. Effects of meal and incretins in the regulation of splanchnic blood flow. Endocr Connect 2017;6:179-87.

[879] Fara JW, Salazar AM. Gastric inhibitory polypeptide increases mesenteric blood flow. Proc Soc Exp Biol Med 1978;158:446-8.

[880] Kogire M, Inoue K, Sumi S, Doi R, Yun M, Kaji H, et al. Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. Dig Dis Sci 1992;37:1666-70.

[881] Asmar M, Simonsen L, Arngrim N, Holst JJ, Dela F, Bulow J. Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes 2014;38:259-65.

[882] Zhong Q, Bollag RJ, Dransfield DT, Gasalla-Herraiz J, Ding KH, Min L, et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides 2000;21:1427-32.

[883] Ding KH, Zhong Q, Isales CM. Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. Am J Physiol Endocrinol Metab 2003;285:E390-6.

[884] Ojima A, Matsui T, Maeda S, Takeuchi M, Yamagishi S. Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res 2012;44:501-5.

[885] Mori Y, Fukushima H, Koshibu M, Saito T, Hiromura M, Kohashi K, et al. Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial remodeling in male mice. Endocrinology 2018;159:2717-32.

[886] Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008;199:237-47.

[887] Jankowich M, Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med 2020;30:1-8.

[888] Lin R, Junttila J, Piuhola J, Lepojarvi ES, Magga J, Kiviniemi AM, et al. Endothelin-1 is associated with mortality that can be attenuated with high intensity statin therapy in patients with stable coronary artery disease. Commun Med 2023;3:87.

[889] Ding KH, Zhong Q, Xu J, Isales CM. Glucose-dependent insulinotropic polypeptide: differential effects on hepatic artery vs. portal vein endothelial cells. Am J Physiol Endocrinol Metab 2004;286:E773-9.

[890] Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci 2018;19.

[891] Rapoport RM. Nitric oxide inhibition of endothelin-1 release in the vasculature: in vivo relevance of in vitro findings. Hypertension 2014;64:908-14.

[892] Lim DM, Park KY, Hwang WM, Kim JY, Kim BJ. Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response. Exp Ther Med 2017;13:2558-64.

[893] Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993;191:1081-8.

[894] Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994;344:1405-6.

[895] Fan J, Unoki H, Iwasa S, Watanabe T. Role of endothelin-1 in atherosclerosis. Ann N Y Acad Sci 2000;902:84-93. ; discussion 93-84.

[896] Miyauchi T, Sugishita Y, Matsuda M, Sakai H, Suzuki N, Masaki T, et al. Increased plasma concentration of endothelin-1 in cholesterol-fed rats. Atherosclerosis 1992;93:257-9.

[897] Uyama H, Haraoka S, Shimokama T, Goto K, Dohi K, Watanabe T. Diet-induced hypercholesterolemia increases endothelin-1 release by aortic endothelial cells. Pathobiology 1996;64:328-32.

[898] Haak T, Marz W, Jungmann E, Hausser S, Siekmeier R, Gross W, et al. Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Invest 1994;72:580-4.
[899] Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995;146:819-26.

[900] Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998;95:14367-72.

[901] Kadoglou NPE, Khattab E, Velidakis N, Gkoukoudi E. The role of osteopontin in atherosclerosis and its clinical manifestations (atherosclerotic cardiovascular diseases)-A narrative review. Biomedicines 2023;11.

[902] Jujic A, Nilsson PM, Atabaki-Pasdar N, Dieden A, Tuomi T, Franks PW, et al. Glucose-dependent insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness. Diabetes Care 2021;44:224-30.

[903] Sachs S, Gotz A, Finan B, Feuchtinger A, DiMarchi RD, Doring Y, et al. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovasc Diabetol 2023;22:217.

[904] Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretin s prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011;54:2649-59.

[905] Nogi Y, Nagashima M, Terasaki M, Nohtomi K, Watanabe T, Hirano T. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One 2012;7:e35683.

[906] Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013;8:e70933.

[907] Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011;91:327-87.

[908] Pujadas G, Baggio LL, Kaur KD, McLean BA, Cao X, Drucker DJ. Genetic disruption of the Gipr in Apoe(-/-) mice promotes atherosclerosis. Mol Metabol 2022;65:101586.

[909] Moffett RC, Naughton V. Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides 2020;125:170233.

[910] Sridhar A, Khan D, Moffett RC. The impact of diabetes and obesity on fertility and the potential role of gut hormones as treatment. Diabet Med 2023;40: e15230.

[911] Samarasinghe SNS, Leca B, Alabdulkader S, Dimitriadis GK, Davasgaium A, Thadani P, et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. Lancet 2024;403:2489-503.

[912] Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ, Liang IT. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2014;99: E2539-48.

[913] Milewicz T, Migacz K, Kialka M, Rogatko I, Kowalczuk A, Spalkowska M, et al. Basic and meal stimulated plasma GIP levels are higher in lean PCOS women with FAI over 5. Exp Clin Endocrinol Diabetes 2016;124:77-81.

[914] Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2008;159: 121-7.

[915] Cassar S, Teede HJ, Harrison CL, Joham AE, Moran LJ, Stepto NK. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: characteristics and predictive capacity. Clin Endocrinol 2015;83:50-8.

[916] Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009;58:586-93.

[917] McConnell JG, Alam MJ, O'Hare MM, Buchanan KD, Stout RW. The effect of age and sex on the response of enteropancreatic polypeptides to oral glucose. Age Ageing 1983;12:54-62.

[918] Sztefko K, Rogatko I, Milewicz T, Jozef K, Tomasik PJ, Szafran Z. Effect of hormone therapy on the enteroin spherical axis. Menopause 2005;12:630-8.

[919] Nishiyama Y, Hasegawa T, Fujita S, Iwata N, Nagao S, Hosoya T, et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells. J Steroid Biochem Mol Biol 2018;178:82-8.

[920] Khan D, Sridhar A, Flatt PR, Moffett RC. Disturbed ovarian morphology, oestrous cycling and fertility of high fat fed rats are linked to alterations of incretin receptor expression. Reprod Biol 2023;23:100784.

[921] Shimizu T, Sato T, Tsukiyama K, Fujita H, Kato S, Hoizumi M, et al. Food intake affects sperm-egg fusion through the GIP/PSG17 Axis in mice. Endocrinology 2017;158:2134-44.

[922] Ottlecz A, Samson WK, McCann SM. The effects of gastric inhibitory polypeptide (GIP) on the release of anterior pituitary hormones. Peptides 1985;6: 115-9.

[923] Gault VA, Holscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J Neurophysiol 2008;99:1590-5.

[924] Porter DW, Irwin N, Flatt PR, Holscher C, Gault VA. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 2011;650:688-93.

[925] Faivre E, Gault VA, Thorens B, Holscher C. Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol 2011;105:1574-80.

[926] Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010;5:109-17.

[927] Holscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases. Front Synaptic Neurosci 2022;14:955258.

[928] Ji C, Xue GF, Li G, Li D, Holscher C. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease. Rev Neurosci 2016;27:61-70.

[929] Zhang ZQ, Holscher C. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. Peptides 2020;125:170184.

[930] Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 2021;70:2545-53.

[931] Borner T, Reiner BC, Crist RC, Furst CD, Doebley SA, Halas JG, et al. GIP receptor agonism blocks chemotherapy-induced nausea and vomiting. Mol Metabol 2023;73:101743.

[932] Samms RJ, Cosgrove R, Snider BM, Furber EC, Droz BA, Briere DA, et al. GIPR agonism inhibits PYY-induced nausea-like behavior. Diabetes 2022;71: 1410-23.

[933] Lorenz DN, Kreielsheimer G, Smith GP. Effect of cholecystokinin, gastrin, secretin and GIP on sham feeding in the rat. Physiol Behav 1979;23:1065-72.

[934] Woods SC, West DB, Stein LJ, McKay LD, Lotter EC, Porte SG, et al. Peptides and the control of meal size. Diabetologia 1981;20:305-13.

[935] Mroz PA, Finan B, Gelfanov V, Yang B, Tschop MH, DiMarchi RD, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metabol 2019;20:51-62.

[936] Han W, Wang L, Ohbayashi K, Takeuchi M, O'Farrell L, Coskun T, et al. Glucose-dependent insulinotropic polypeptide counteracts diet-induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin-responsive and proopiomelanocortin neurons in the arcuate nucleus. Diabetes Obes Metabol 2023;25:1534-46.
[937] Ambati S, Duan J, Hartzell DL, Choi YH, Della-Fera MA, Baile CA. GIP-dependent expression of hypothalamic genes. Physiol Res 2011;60:941-50.

[938] NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun 2017;490:247-52.

[939] Kaneko K, Fu Y, Lin HY, Cordonier EL, Mo Q, Gao Y, et al. Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Investig 2019;129:3786-91.

[940] Lee S, Tong M, Hang S, Deochand C, de la Monte S. CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer's disease. J Alzheimers Dis Parkinsonism 2013;3:128.

[941] Faivre E, Holscher C. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther 2013;5:20.

[942] Yu CJ, Ma D, Song LL, Zhai ZN, Tao Y, Zhang Y, et al. The role of GLP-1/GIP receptor agonists in Alzheimer's disease. Adv Clin Exp Med 2020;29:661-8.

[943] Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des 2016;22:1177-93.

[944] Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig 2014;124:4473-88.

[945] Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alantenalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020;5.

[946] Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochem Pharmacol 2020;180:114187.

[947] Rodriguez EM, Blazquez JL, Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides 2010;31:757-76.

[948] Haddad-Tovolli R, Dragano NRV, Ramalho AFS, Velloso LA. Development and function of the blood-brain barrier in the context of metabolic control. Front Neurosci 2017;11:224.

[949] Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab 2022;34:1054-1063 e1057.

[950] Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, et al. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Mol Metabol 2022;55:101407.

[951] Zhang C, Vincelette LK, Reimann F, Liberles SD. A brainstem circuit for nausea suppression. Cell Rep 2022;39:110953.

[952] Ludwig MQ, Todorov PV, Egerod KL, Olson DP, Pers TH. Single-cell mapping of GLP-1 and GIP receptor expression in the dorsal vagal complex. Diabetes 2021;70:1945-55.

[953] Cheng W, Gordian D, Ludwig MQ, Pers TH, Seeley RJ, Myers Jr MG. Hindbrain circuits in the control of eating behaviour and energy balance. Nat Metab 2022;4:826-35.

[954] Carter ME, Soden ME, Zweifel LS, Palmiter RD. Genetic identification of a neural circuit that suppresses appetite. Nature 2013;503:111-4.

[955] Izadi MS, Radahmadi M. Overview of the central amygdala role in feeding behaviour. Br J Nutr 2022;127:953-60.

[956] Affinati AH, Myers Jr MG. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Neuroendocrine control of body energy homeostasis. South Dartmouth (MA: Endotext; 2000).

[957] Pauli JL, Chen JY, Basiri ML, Park S, Carter ME, Sanz E, et al. Molecular and anatomical characterization of parabrachial neurons and their axonal projections. Elife 2022;11.

[958] McMorrow HE, Lorch CM, Hayes NW, Fleps SW, Frydman JA, Xia JL, et al. Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite. bioRxiv; 2024.

[959] Asmar M, Tangaa W, Madsbad S, Hare K, Astrup A, Flint A, et al. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 2010;298:E614-21.

[960] Bergmann NC, Gasbjerg LS, Heimburger SM, Krogh LSL, Dela F, Hartmann B, et al. No acute effects of exogenous glucose-dependent insulintropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes. Diabetes Care 2020;43:588-96.

[961] Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, Mather KJ, et al. A long-acting glucose dependent insulintropic polypeptide receptor agonist shows weight loss without nausea or vomiting. In: American Diabetes Association — 83rd Annual Scientific Sessions; San Diego, CA, USA; 23 — 26 June 2023; 2023.

[962] Portron A, Jadidi S, Sarkar N, DiMarchi R, Schmitt C. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulintropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Diabetes Obes Metabol 2017;19:1446-53.

[963] Schmitt C, Portron A, Jadidi S, Sarkar N, DiMarchi R. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulintropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metabol 2017;19:1436-45.

[964] Frias JP, Bastyr 3rd EJ, Vignati L, Tschop MH, Schmitt C, Owen K, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 2017;26:343-352 e342.

[965] Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Investig 2021;131.

[966] Wean J, Kowalsky AH, Laker R, Will S, Drucker DJ, Rhodes CJ, et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Mol Metabol 2024;102074.

[967] El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab 2023 Jun;5(6):945-54. https://doi.org/10.1038/s42255-023-00811-0.

[968] Yuliantie E, Darbalaei S, Dai A, Zhao P, Yang D, Sexton PM, et al. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol 2020;177:114001.

[969] Brown KA, Morris RK, Eckhardt SJ, Ge Y, Gellman SH. Phosphorylation sites of the gastric inhibitory polypeptide receptor (GIPR) revealed by trapped-ion-mobility spectrometry coupled to time-of-flight mass spectrometry (TIMS-TOF MS). J Am Chem Soc 2023;145:28030-7.

[970] Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55.

[971] Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin deglucide as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98.

[972] Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022;327:534-45.

[973] Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased
cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24.

[974] Rosenstock J, Frias JP, Rodbard HW, Tofe S, Sears E, Huh R, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA 2023;330:1631-40.

[975] Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 2022;10:623-33.

[976] Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 2022;10:634-44.

[977] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387: 205-16.

[978] Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613-26.

[979] Gao L, Lee BW, Chawla M, Kim J, Huo L, Du L, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 2023;29: 1500-10.

[980] Jumpertz von Schwartzenberg R, Vazquez Arreola E, Sandforth A, Hanson RL, Birkenfeld AL. Role of weight loss-induced prediabetes remission in the prevention of type 2 diabetes: time to improve diabetes prevention. Diabetologia 2024;67:1714-8.

[981] Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29: 2909-18.

[982] Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331: 38-48.

[983] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Baker C, Gluckman TJ, Stucky NL. Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: a real-world evidence study. medRxiv 2023. https://doi.org/10.1101/ 2023.11.21.23298775.

[984] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-91.

[985] Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-84.

[986] Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev 2023;24: e13543.

[987] Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024 Jul 25;391(4):299-310. https://doi.org/ 10.1056/NEJMoa2401943.

[988] Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redine S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1464.

[989] Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep 2023;13:20998.

[990] Kleinert M, Sachs S, Habegger KM, Hofmann SM, Muller TD. Glucagon regulation of energy expenditure. Int J Mol Sci 2019;20.

[991] Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, et al. 100 years of glucagon and 100 more. Diabetologia 2023;66: 1378-94.

[992] Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013;62:1453-63.

[993] Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, et al. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metabol 2017;6:440-6.

[994] Mansur SA, Mieczkowska A, Flatt PR, Bouvard B, Chappard D, Irwin N, et al. A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mel- litus. Bone 2016;87:102-13.

[995] Choi IY, Kim JK, Lee JS, Park E, Kim YH, Jung SY, et al. Effect of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in a NASH and fibrosis animal model. Diabetes 2018;67.

[996] Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjollund KR, He Y, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metabol 2022;63:101533.

[997] Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 2022;34:1234-1247 e1239.

[998] Bossart M, Wagner M, Elvert R, Evers A, Hubschle T, Kloeckener T, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab 2022;34: 59-74 e10.

[999] Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, rando- mised, multiple-ascending dose trial. Lancet 2022;400:1869-81.

[1000] Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple- hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 2023;389:514-26.

[1001] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatoxic liver disease: a randomized phase 2a trial. Nat Med 2024 Jul;30(7):2037-48. https://doi.org/10.1038/s41591-024-03018-2.

[1002] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Reta- trutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, par- allel-group, phase 2 trial conducted in the USA. Lancet 2023;402:529-44.

[1003] Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, Mather KJ, et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes Metabol 2024 Nov;26(11):5474-8. https:// doi.org/10.1111/dom.15875.

[1004] Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, et al. Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care 2019;42:1446-53.

[1005] Irwin N, Hunter K, Montgomery IA, Flatt PR. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Diabetes Obes Metabol 2013;15:650-9.
[1006] Craig SL, Perry RA, Vyavahare SS, Ng MT, Gault VA, Flatt PR, et al. A GIP/ xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice. Biochem Pharmacol 2020;171:113723.

[1007] Franklin ZJ, McDonnell B, Montgomery IA, Flatt PR, Irwin N. Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide. Diabetes Obes Metabol 2011;13:742-9.

[1008] Bates HE, Campbell JE, Ussher JR, Baggio LL, Maida A, Seino Y, et al. Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(-/-) mice. Diabetes 2012;61:40-8.

[1009] Ugleholdt R, Pedersen J, Bassi MR, Fuchtbauer EM, Jorgensen SM, Kissow HL, et al. Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J Biol Chem 2011;286:44632-45.

[1010] Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 2005;335: 937-42.

[1011] Nakamura T, Tanimoto H, Mizuno Y, Okamoto M, Takeuchi M, Tsubamoto Y, et al. Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice. Obes Sci Pract 2018;4:194-203.

[1012] Nakamura T, Tanimoto H, Okamoto M, Takeuchi M, Tsubamoto Y, Noda H. GIP receptor antagonist, SKL-14959 indicated alteration of the lipids metabolism to catabolism by the inhibition of plasma LPL activity, resulting in the suppression of weight gain on diets-induced obesity mice. Diabetes Metab Syndr Obes 2021;14:1095-105.

[1013] Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonist protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007;50:1752-62.

[1014] Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007;50:1532-40.

[1015] McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 2007;293:E1746-55.

[1016] Fulurija A, Lutz TA, Sladko K, Osto M, Wielinga PY, Bachmann MF, et al. Vaccination against GIP for the treatment of obesity. PLoS One 2008;3:e3163.

[1017] Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem 2009;390:75-80.

[1018] Irwin N, Montgomery IA, Flatt PR. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice. Br J Nutr 2012;108:46-56.

[1019] Montgomery IA, Irwin N, Flatt PR. Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice. Diabetes Obes Metabol 2010;12:744-51.

[1020] Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-48.

[1021] Vogel CI, Scherag A, Bronner G, Nguyen TT, Wang HJ, Grallert H, et al. Gastric inhibitory polypeptide receptor: association analyses for obesity of several polymorphisms in large study groups. BMC Med Genet 2009;10:19.

[1022] Pathak V, Gault VA, Flatt PR, Irwin N. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 2015;401:120-9.

[1023] Singh SK, Bartoo AC, Krishnan S, Boylan MO, Schwartz JH, Michael Wolfe M. Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport. Obesity 2008;16:2412-6.

[1024] Jensen MH, Sanni SJ, Riber D, Holst JJ, Rosenkilde MM, Sparre-Ulrich AH. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys. Mol Metabol 2024;88:102006.

[1025] Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroin singular axis. Am J Physiol Endocrinol Metab 2003;284:E931-9.

[1026] Ahren B, Yamada Y, Seino Y. Islet adaptation in GIP receptor knockout mice. Peptides 2020;125:170152.

[1027] Cani PD, Holst JJ, Drucker DJ, Delzenne NM, Thorens B, Burcelin R, et al. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol 2007;276:18-23.

[1028] Galsgaard KD, Kissow HL, Smits MM, Holst JJ. SAT037 glucagon-like peptide-1 receptor knockout mice do not compensate for the lack of incretin action by increasing glucose-dependent insulinotropic polypeptide secretion. J Endocr Soci 2023;7(Suppl 1): bvd114-905.

[1029] Killian EA, Wang J, Yie J, Shi SD, Bates D, Min X, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med 2018;10.

[1030] Boer GA, Hunt JE, Gabe MBN, Windelov JA, Sparre-Ulrich AH, Hartmann B, et al. Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed mice. Br J Pharmacol 2022;179:4486-99.

[1031] Yang B, Gelfanov VM, El K, Chen A, Rohlf s R, DuBois B, et al. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems. Mol Metabol 2022;66:101638.

[1032] Lu SC, Chen M, Atangan L, Killian EA, Komorowski R, Cheng Y, et al. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Rep Med 2021;2: 100263.

[1033] Veniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab 2024;6:290-303.

[1034] Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists. J Clin Endocrinol Metab 2020;105:e2710-6.

[1035] Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, et al. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 1998;41:1194-8.

[1036] Rogers M, Gill D, Ahlqvist E, Robinson T, Mariosa D, Johansson M, et al. Genetically proxied impaired GIPR signaling and risk of 6 cancers. iScience 2023;26:106848.

[1037] Davies I, Adriaenssens AE, Scott WR, Carling D, Murphy KG, Minnion JS, et al. Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation. Mol Metabol 2025:102094.

[1038] Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
[1039] Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.

[1040] Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.

[1041] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.

[1042] Knop FK, Urva S, Rettiganti M, Benson CT, Roell WC, Mather KJ, et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. In: European Association for the Study of Diabetes - 59th Annual Meeting; Hamburg, Germany; 2 - 6 October 2023; 2023.

[1043] Borner T, De Jonghe BC, Hayes MR. The antiemetic actions of GIP receptor agonism. Am J Physiol Endocrinol Metab 2024;326:E528-36.

[1044] Babic T, Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol 2014;722:38-47.

[1045] Borison HL, Borison R, McCarthy LE. Role of the area postrema in vomiting and related functions. Fed Proc 1984;43:2955-8.

[1046] Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994;15:301-20.

[1047] De Jonghe BC, Holland RA, Olivos DR, Rupprecht LE, Kanoski SE, Hayes MR. Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. Physiol Behav 2016;153:109-14.

[1048] De Jonghe BC, Horn CC. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J Physiol Regul Integr Comp Physiol 2009;296: R902-11.

[1049] Horn CC, Ciucci M, Chaudhury A. Brain Fos expression during 48 h after cisplatin treatment: neural pathways for acute and delayed visceral sickness. Auton Neurosci 2007;132:44-51.

[1050] Miller AD, Ruggiero DA. Emetic reflex arc revealed by expression of the immediate-early gene c-fos in the cat. J Neurosci 1994;14:871-88.

[1051] Carpenter DO, Briggs DB, Knox AP, Strominger NL. Radiation-induced emesis in the dog: effects of lesions and drugs. Radiat Res 1986;108:307-16.

[1052] Harding RK, Hugenholtz H, Keaney M, Kucharczyk J. Discrete lesions of the area postrema abolish radiation-induced emesis in the dog. Neurosci Lett 1985;53:95-100.

[1053] Laffan RJ, Borison HL. Emetic action of nicotine and lobeline. J Pharmacol Exp Therapeut 1957;121:468-76.

[1054] Harding RK, McDonald TJ. Identification and characterization of the emetic effects of peptide YY. Peptides 1989;10:21-4.

[1055] Thiele TE, Seeley RJ, D'Alessio D, Eng J, Bernstein IL, Woods SC, et al. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 1998;801:164-70.

[1056] Fortin SM, Chartoff EH, Roitman MF. The aversive agent lithium chloride suppresses phasic dopamine release through central GLP-1 receptors. Neuropsychopharmacology 2016;41:906-15.

[1057] Faivre E, Hamilton A, Holscher C. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur J Pharmacol 2012;674:294-306.

[1058] Jalewa J, Sharma MK, Holscher C. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J Neurochem 2016;139:55-67.

[1059] Maino B, Ciotti MT, Calissano P, Cavallaro S. Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide. Int J Mol Sci 2014;15:5596-622.

[1060] Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001;294:1030-8.

[1061] Lamsa K, Lau P. Long-term plasticity of hippocampal interneurons during in vivo memory processes. Curr Opin Neurobiol 2018;54:20-7.

[1062] Ding KH, Zhong Q, Xie D, Chen HX, Della-Fera MA, Bollag RJ, et al. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 2006;27: 2750-5.

[1063] Faivre E, Hamilton A, Holscher C. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur J Pharmacol 2012;674:294-306.

[1064] Figueiredo CP, Pamplona FA, Mazzuco TL, Aguiar Jr AS, Walz R, Prediger RD. Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav Pharmacol 2010;21:394-408.

[1065] Buhren BA, Gasis M, Thorens B, Muller HW, Bosse F. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 2009;87:1858-70.

[1066] Marcos AB, Forner S, Martini AC, Patricio ES, Clarke JR, Costa R, et al. Temporal and regional expression of glucose-dependent insulinotropic peptide and its receptor in spinal cord injured rats. J Neurotrauma 2016;33: 261-8.

[1067] Gault VA, Flatt PR, O'Harte FP. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003;308: 207-13.

[1068] Duffy AM, Holscher C. The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 2013;228:294-300.

[1069] Faivre E, Holscher C. Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther 2013;5:20-8.

[1070] Faivre E, Holscher C. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. J Alzheimer Dis : JAD 2013;35:267-83.

[1071] Yuan L, Zhang J, Guo JH, Holscher C, Yang JT, Wu MN, et al. DAla2-GIP- GLU-PAL protects against cognitive deficits and pathology in APP/PS1 mice by inhibiting neuroinflammation and upregulating cAMP/PKA/CREB signaling pathways. J Alzheimer Dis : JAD 2021;80:695-713.

[1072] Kopin IJ, Markey SP. MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 1988;11:81-96.

[1073] Li Y, Liu W, Li L, Holscher C. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology 2016;101: 255-63.

[1074] Li Y, Liu W, Li L, Holscher C. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation. Eur J Pharmacol 2017;797:162-72.

[1075] Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & therapeutics 2013;138:155-75.

[1076] Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011;10: 209-19.

[1077] Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 2009;106: 13594-9.

[1078] Verma MK, Goel R, Nandakumar K, Nemmani KV. Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice. Eur J Pharmacol 2017;804:38-45.
[1079] Yu YW, Hsueh SC, Lai JH, Chen YH, Kang SJ, Chen KY, et al. Glucose-dependent insulinotropic polypeptide mitigates 6-OHDA-induced behavioral impairments in Parkinsonian rats. Int J Mol Sci 2018;19.

[1080] Yang S, Zhao X, Zhang Y, Tang Q, Li Y, Du Y, et al. Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice. Peptides 2024;179:171271.

[1081] Fontanella RA, Ghosh P, Pesapane A, Taktaz F, Puocci A, Franzese M, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med 2024;22:114.

[1082] Meissner W, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto J, et al. Trial of lixisenatide in early Parkinson's disease. N Engl J Med 2024;390:1176-85.

[1083] Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Lancet 2017;390:1664-75.

[1084] Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology 2018;136:260-70.

[1085] Edison P, Femminella G, Ritchie C, Holmes C, Walker Z, Ridha B, et al. Evaluation of liraglutide in the treatment of Alzheimer's disease. Alzheimer & Dementia 2022;17:S9.

[1086] Edison P, Walker Z, Coulthard E, Hölscher C, Passmore A, Ballard C. MRI changes following treatment of GLP-1 analogue, liraglutide in ALZHEIMER'S disease: ELAD trial. Alzheimer's Dementia 2023;19:S21.

[1087] Holscher C. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making? Neuropharmacology 2024;253:109952.

[1088] Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, et al. A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson's disease. Available at: SSRN. 2023. https://doi.org/10.2139/ssrn.4212371. https://ssrn.com/abstract=4212371.

[1089] Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, et al. Long-term treatment with liraglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, has No effect on beta-amyloid plaque load in two transgenic APP/PS1 mouse models of alzheimer's disease. PLoS One 2016;11:e0158205.

[1090] Forny Germano L, Koehler JA, Baggio LL, Cui F, Wong CK, Rittig N, et al. The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice. Mol Metabol 2024;89:102019.

[1091] Rhea EM, Babin A, Thomas P, Omer M, Weaver R, Hansen K, et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases. Tissue Barriers 2023:2292461.

[1092] Feng P, Zhang X, Li D, C, J, Yuan Z, Wang R, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology 2018;133:385-94.

[1093] Cao L, Li D, Feng P, Li L, Xue G, Li G, et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport 2016;37:384-91.

[1094] Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res 2016;1634:1-11.

[1095] Jalewa J, Sharma M, Gengler S, Hölscher C. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. Neuropharmacology 2017;117:238-48.

[1096] Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-94.

[1097] Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C. Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease. Neuroscience 2015;303:42-50.

[1098] Panagaki T, Gengler S, Holscher C. The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE/PS1DeltaE9 mouse model. J Alzheimer Dis: JAD 2018;66:195-218.

[1099] Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, et al. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. Eur J Pharmacol 2017;812:82-90.

[1100] Zhang L, Zhang L, Li Y, Li L, Melchiorsen J, Rosenkilde M, et al. The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease. J Parkinson Dis 2020;10:523-42.

[1101] Zhang L, Li C, Zhang Z, Zhang Z, Jin QQ, Li L, et al. DA5-CH and semaglutide protect against neurodegeneration and reduce alpha-synuclein levels in the 6-OHDA Parkinson's disease rat model. Parkinsons Dis 2022;2022:1428817.

[1102] Zhang LY, Jin QQ, Holscher C, Li L. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen Res 2021;16:1660-70.

[1103] Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, Holscher C. The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of alzheimer's disease. Am J Alzheimers Dis Other Demen 2020;35:1533317520953041.

[1104] Shi L, Zhang Z, Li L, Holscher C. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res 2017;327:65-74.

[1105] Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimer Dis: JAD 2005;7:63-80.

[1106] Knezovic A, Osmanovic Barilar J, Babic A, Bagaric R, Farkas V, Riederer P, et al. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease. Neuropharmacology 2018;135:48-62.

[1107] Cai HY, Yang D, Qiao J, Yang JT, Wang ZJ, Wu MN, et al. A GLP-1/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP/PS1/Tau model of Alzheimer's disease. J Alzheimer Dis: JAD 2021;83:799-818.

[1108] Zhang Z, Shi M, Li Z, Ling Y, Zhai L, Yuan Y, et al. A dual GLP-1/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson's disease. Parkinsons Dis 2023;2023:7427136.